JP2021531346A5 - - Google Patents
Info
- Publication number
- JP2021531346A5 JP2021531346A5 JP2021526403A JP2021526403A JP2021531346A5 JP 2021531346 A5 JP2021531346 A5 JP 2021531346A5 JP 2021526403 A JP2021526403 A JP 2021526403A JP 2021526403 A JP2021526403 A JP 2021526403A JP 2021531346 A5 JP2021531346 A5 JP 2021531346A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701467P | 2018-07-20 | 2018-07-20 | |
| US62/701,467 | 2018-07-20 | ||
| PCT/US2019/042597 WO2020023310A1 (en) | 2018-07-20 | 2019-07-19 | Compositions of fcrn antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531346A JP2021531346A (ja) | 2021-11-18 |
| JP2021531346A5 true JP2021531346A5 (enExample) | 2022-06-20 |
| JP7457704B2 JP7457704B2 (ja) | 2024-03-28 |
Family
ID=69180697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526403A Active JP7457704B2 (ja) | 2018-07-20 | 2019-07-19 | Ｆｃｒｎ抗体の組成物およびその使用の方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210299255A1 (enExample) |
| EP (1) | EP3826641A4 (enExample) |
| JP (1) | JP7457704B2 (enExample) |
| KR (1) | KR20210105872A (enExample) |
| CN (1) | CN113301903A (enExample) |
| AU (1) | AU2019312139B2 (enExample) |
| BR (1) | BR112021001017A2 (enExample) |
| CA (1) | CA3106669A1 (enExample) |
| CR (1) | CR20210088A (enExample) |
| EA (1) | EA202190335A1 (enExample) |
| IL (1) | IL280280B2 (enExample) |
| JO (2) | JOP20210015A1 (enExample) |
| MX (1) | MX2021000790A (enExample) |
| PH (1) | PH12021550096A1 (enExample) |
| SG (1) | SG11202100420UA (enExample) |
| WO (1) | WO2020023310A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| CN116782939A (zh) * | 2020-11-06 | 2023-09-19 | 动量制药公司 | FcRn抗体及其使用方法 |
| CA3200972A1 (en) * | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| MX2023012032A (es) * | 2021-04-12 | 2023-12-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
| EP4658368A1 (en) | 2023-02-04 | 2025-12-10 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| CN116539488B (zh) * | 2023-05-11 | 2023-11-24 | 中国食品药品检定研究院 | 一种体外评价生物制品稳定性的方法、系统及设备 |
| TW202527982A (zh) * | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2025259928A1 (en) * | 2024-06-13 | 2025-12-18 | Obi Pharma, Inc. | Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof |
| WO2026083290A1 (en) | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03504499A (ja) * | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| WO2003068260A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| EP2225269A2 (en) * | 2007-11-09 | 2010-09-08 | Anaphore, Inc. | Fusion proteins of mannose binding lectins for treatment of disease |
| WO2009124294A2 (en) | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) * | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| JP2018527903A (ja) * | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | Ｇｄｆ１１結合タンパク質およびその使用 |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
-
2019
- 2019-07-19 IL IL280280A patent/IL280280B2/en unknown
- 2019-07-19 AU AU2019312139A patent/AU2019312139B2/en active Active
- 2019-07-19 BR BR112021001017-3A patent/BR112021001017A2/pt unknown
- 2019-07-19 KR KR1020217003706A patent/KR20210105872A/ko not_active Abandoned
- 2019-07-19 CA CA3106669A patent/CA3106669A1/en active Pending
- 2019-07-19 JO JOP/2021/0015A patent/JOP20210015A1/ar unknown
- 2019-07-19 CR CR20210088A patent/CR20210088A/es unknown
- 2019-07-19 CN CN201980061788.8A patent/CN113301903A/zh active Pending
- 2019-07-19 EA EA202190335A patent/EA202190335A1/ru unknown
- 2019-07-19 JP JP2021526403A patent/JP7457704B2/ja active Active
- 2019-07-19 US US17/260,318 patent/US20210299255A1/en not_active Abandoned
- 2019-07-19 EP EP19840439.4A patent/EP3826641A4/en not_active Withdrawn
- 2019-07-19 PH PH1/2021/550096A patent/PH12021550096A1/en unknown
- 2019-07-19 JO JOP/2021/0014A patent/JOP20210014A1/ar unknown
- 2019-07-19 MX MX2021000790A patent/MX2021000790A/es unknown
- 2019-07-19 WO PCT/US2019/042597 patent/WO2020023310A1/en not_active Ceased
- 2019-07-19 SG SG11202100420UA patent/SG11202100420UA/en unknown